BIOVIE INC. - COMMON STOCK

BioVie to Present Blinded Data on NE3107 in the Treatment of Mild to Moderate Alzheimer’s Disease at CTAD

19 أكتوبر 2023 06:30:00 بحسب Nasdaq GlobeNewswire

BioVie Announces Completion of Last Patient Treatment Visit in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer's Disease

26 سبتمبر 2023 07:00:01 بحسب Nasdaq GlobeNewswire

BioVie to Participate in the Cantor Fitzgerald Global Healthcare Conference

19 سبتمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

BioVie Presents Data Highlighting Baseline Characteristics of Study Population in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer’s Disease

11 سبتمبر 2023 07:00:01 بحسب Nasdaq GlobeNewswire

BioVie Hosting Virtual KOL Event on NE3107 in Alzheimer’s Disease Today, September 7, 2023

07 سبتمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

BioVie to Host Virtual KOL Event on NE3107 in Alzheimer’s Disease on September 7, 2023

31 أغسطس 2023 07:00:00 بحسب Nasdaq GlobeNewswire

BioVie Presents Data for NE3107 at 2023 International Congress of Parkinson’s Disease and Movement Disorders

28 أغسطس 2023 07:00:00 بحسب Nasdaq GlobeNewswire

BioVie Issues Letter to Shareholders

18 يوليو 2023 06:00:00 بحسب Nasdaq GlobeNewswire

BioVie Presents Data Showing How NE3107 May Potentially Regulate DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease

17 يوليو 2023 06:00:00 بحسب Nasdaq GlobeNewswire

BioVie to Present Data Showing How NE3107 Potentially Regulates DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease

10 يوليو 2023 07:00:00 بحسب Nasdaq GlobeNewswire

BioVie Presents Data Highlighting Role of Insulin Resistance and Neuroinflammation in the Development of Mild to Moderate in Alzheimer’s Disease

26 يونيو 2023 07:00:00 بحسب Nasdaq GlobeNewswire

BioVie Set to Join the Russell 2000® and Russell 3000® Indexes

23 يونيو 2023 07:00:00 بحسب Nasdaq GlobeNewswire

BioVie To Present of NE3017 in Alzheimer’s Disease Data at 83rd Scientific Sessions of the American Diabetes Association

21 يونيو 2023 07:00:00 بحسب Nasdaq GlobeNewswire

BioVie Presents Rationale for Potentially Pivotal Trial of NE3107 in the Treatment of Parkinson’s Disease at 2023 International Association of Parkinsonism and Related Disorders World Congress

16 مايو 2023 15:05:00 بحسب Nasdaq GlobeNewswire

BioVie To Present Data from NE3107 Phase 2 Open-Label Trial at Society of Biological Psychiatry Annual Meeting

20 أبريل 2023 07:30:00 بحسب Nasdaq GlobeNewswire

BioVie Announces Data Abstracts from NE3107 Phase 2 Trials Accepted for Presentation at AAN 2023

17 أبريل 2023 07:00:01 بحسب Nasdaq GlobeNewswire

BioVie Announces Data from Phase 2 Parkinson’s Disease Trial Accepted for Presentation at AD/PD 2023

21 مارس 2023 07:01:00 بحسب Nasdaq GlobeNewswire

BioVie Announces Registration Details for "BioVie Day" Webinar

14 مارس 2023 07:00:00 بحسب Nasdaq GlobeNewswire

BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial

13 مارس 2023 07:00:01 بحسب Nasdaq GlobeNewswire

BioVie to Participate in the Oppenheimer 33rd Annual Healthcare Conference

09 مارس 2023 07:00:01 بحسب Nasdaq GlobeNewswire